The estimated Net Worth of Jin Long Chen is at least $12.3 Milión dollars as of 17 January 2023. Jin Chen owns over 85,082 units of Ngm Biopharmaceuticals Inc stock worth over $1,530,722 and over the last 5 years he sold NGM stock worth over $8,885,300. In addition, he makes $1,917,600 as Founder, Chief Scientific Officer a Director at Ngm Biopharmaceuticals Inc.
Sign up
Jin Chen NGM stock SEC Form 4 insiders trading
Jin has made over 21 trades of the Ngm Biopharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 85,082 units of NGM stock worth $122,518 on 17 January 2023.
The largest trade he's ever made was exercising 150,000 units of Ngm Biopharmaceuticals Inc stock on 4 January 2021 worth over $90,000. On average, Jin trades about 40,560 units every 47 days since 2019. As of 17 January 2023 he still owns at least 993,975 units of Ngm Biopharmaceuticals Inc stock.
You can see the complete history of Jin Chen stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Jin-Long Chen biography
Dr. Jin-Long Chen Ph.D. serves as Founder, Chief Scientific Officer, Director of the Company. Dr. Chen has served as a member of our Board of Directors and as our Chief Scientific Officer since January 2008. From 2004 to 2008, Dr. Chen held various positions at Amgen, most recently as its Vice President, Metabolic Research. Prior to joining Amgen, Dr. Chen was Vice President, Biology at Tularik. He has served as a director of Tenaya Therapeutics, Inc. since 2016. Dr. Chen received a B.S. from Fu-Jen Catholic University, an M.S. from National Taiwan University and a Ph.D. from the University of California, Berkeley. Chen’s extensive experience with NGM, which is a consequence of his long tenure as Chief Scientific Officer, brings necessary historic knowledge and continuity to our Board of Directors. In addition, we believe that his experiences prior to joining us provided him with operational and industry expertise that are important to our Board of Directors.
What is the salary of Jin Chen?
As the Founder, Chief Scientific Officer a Director of Ngm Biopharmaceuticals Inc, the total compensation of Jin Chen at Ngm Biopharmaceuticals Inc is $1,917,600. There are 1 executives at Ngm Biopharmaceuticals Inc getting paid more, with David Woodhouse having the highest compensation of $2,092,150.
How old is Jin Chen?
Jin Chen is 57, he's been the Founder, Chief Scientific Officer a Director of Ngm Biopharmaceuticals Inc since . There are 8 older and 9 younger executives at Ngm Biopharmaceuticals Inc. The oldest executive at Ngm Biopharmaceuticals Inc is David Goeddel, 68, who is the Lead independent director.
What's Jin Chen's mailing address?
Jin's mailing address filed with the SEC is C/O NGM BIOPHARMACEUTICALS, INC., 333 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080.
Insiders trading at Ngm Biopharmaceuticals Inc
Over the last 6 years, insiders at Ngm Biopharmaceuticals Inc have traded over $9,159,599 worth of Ngm Biopharmaceuticals Inc stock and bought 18,889,291 units worth $177,396,366 . The most active insiders traders include Peter Svennilson, David V Goeddel a Group L P Svennilson Peter .... On average, Ngm Biopharmaceuticals Inc executives and independent directors trade stock every 9 days with the average trade being worth of $171,092. The most recent stock trade was executed by Group L Ptcg Opportunity Ii... on 15 November 2023, trading 22,631 units of NGM stock currently worth $15,615.
What does Ngm Biopharmaceuticals Inc do?
ngm bio is a research-driven, clinical stage biopharmaceutical company with a drug discovery platform designed to generate a pipeline of first-in-class biologic drug candidates. our initial r&d focus has been on cardio-metabolic and liver disease, but we believe that our research expertise – comprehensive and grounded in fundamental, interrelated mechanisms of human biology – is capable of driving the development of new therapies for a wide range of disease areas such as cancer. ngm bio’s comprehensive approach to drug discovery focuses on elucidating the biology of hormones, cell receptors and associated ligands. as we investigate these novel biological mechanisms, we assemble a deep understanding of the relationship between the structure and function of proteins of interest. coupled with our experience in protein and antibody engineering, our approach enables the efficient and targeted generation of potential first-in-class therapeutics with optimized pharmacologic profiles. work
What does Ngm Biopharmaceuticals Inc's logo look like?
Complete history of Jin Chen stock trades at Ngm Biopharmaceuticals Inc
Ngm Biopharmaceuticals Inc executives and stock owners
Ngm Biopharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
David Woodhouse,
Chief Executive Officer, Director -
Jin-Long Chen,
Founder, Chief Scientific Officer, Director -
William Rieflin,
Executive Chairman of the Board of Directors -
Suzanne Hooper,
Independent Director -
Dr. David J. Woodhouse Ph.D.,
CEO & Director -
Dr. Jin-Long Chen Ph.D.,
Founder, Chief Scientific Officer & Director -
Shelly Guyer,
Independent Director -
Siobhan Nolan Mangini,
CFO and Principal Financial & Accounting Officer -
McHenry Tichenor,
Independent Director -
David Goeddel,
Lead independent director -
David Schnell,
Independent Director -
Mark Leschly,
Independent Director -
William J. Rieflin J.D.,
Exec. Chairman of Directors -
Siobhan Mangini,
Chief Financial Officer -
Carole Ho,
Independent Director -
Hsiao Lieu,
Senior Vice President, Chief Medical Officer -
Marc Learned,
Vice President - Research Operations -
Hui Tian,
Senior Vice President - Research -
Wenyan Shen,
Senior Vice President - Biologics and CMC -
Alex DePaoli,
Senior Vice President, Chief Translational Officer -
Valerie Pierce,
Senior Vice President, Chief Compliance Officer, General Counsel, Secretary -
Dr. Hsiao Dee Lieu,
Chief Medical Officer & Sr. VP -
Brian Muma,
VP of HR -
Valerie L. Pierce J.D.,
Sr. VP, Gen. Counsel, Sec. & Chief Compliance Officer -
Alexander Duke Schwartz,
Exec. Director of Investor Relations -
Group L Ptcg Opportunity Ii...,
-
Group L Pcolumn Group Gp, L...,
-
Group L Pcolumn Group Gp, L...,
-
Group L P Svennilson Peter ...,
-
Peter Svennilson,
Director -
Group L Pcolumn Group Ii, L...,
-
Group L Pcolumn Group Iii, ...,
-
Aetna Wun Trombley,
President & COO -
Group L Pcolumn Group Ii, L...,
-
Group L Pcolumn Group Ii, L...,
-
Group L P Ponoi Capital Ii,...,
-
Group L Pcolumn Group Iii, ...,
-
Roger M Perlmutter,
-
Group L Pcolumn Group Gp, L...,
-
Group L Pcolumn Group Iii, ...,
-
Jean Frederic Viret,
Chief Financial Officer -
Group Gp, Lpcolumn Group Ii...,
-
Opportunity Iii Gp, Llc Tcg,
10% owner -
Irene Perlich,
Principal Accounting Officer